MedPath

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Phase 3
Recruiting
Conditions
Ulcerative Colitis
Interventions
Registration Number
NCT05784246
Lead Sponsor
Eli Lilly and Company
Brief Summary

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

Detailed Description

Participants who complete the study will have the option to enter the long-term extension Study I6T-MC-AMAZ (AMAZ).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Males or females weighing ≥10 kg and ≥2 and <18 years old at the time of consent for screening.
  • Have moderate to severe UC.
  • Have failed corticosteroids, biologics, (for example, anti-tumor necrosis factor (TNF) antibodies or anti-integrin antibodies), immunomodulators (for example, azathioprine, thiopurines or methotrexate) or Janus Kinase (JAK)-Inhibitor treatment.
  • Have UC at least 3 months in duration before baseline, which includes endoscopic evidence of UC corroborated by a histopathology report.
Exclusion Criteria
  • Have Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis or primary sclerosing cholangitis.
  • Have immune deficiency syndrome.
  • Previous bowel resection or intestinal surgery.
  • Evidence of toxic megacolon.
  • History or current evidence of cancer of the gastrointestinal tract.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mirikizumab Weight-Based Group 3Mirikizumab IVExperimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
Mirikizumab Weight-Based Group 1Mirikizumab IVExperimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
Mirikizumab Weight-Based Group 1Mirikizumab SCExperimental: Participants will receive mirikizumab weight-based dosing intravenously (IV) or subcutaneously (SC).
Mirikizumab Weight-Based Group 3Mirikizumab SCExperimental: Mirikizumab Participants will receive mirikizumab weight-based dosing IV or SC.
Mirikizumab Weight-Based Group 2Mirikizumab IVExperimental: Participants will receive mirikizumab weight-based dosing IV or SC.
Mirikizumab Weight-Based Group 2Mirikizumab SCExperimental: Participants will receive mirikizumab weight-based dosing IV or SC.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants with modified Mayo score (MMS) Clinical Remission at Week 52 among the Week 12 Clinical RespondersBaseline to Week 52
Secondary Outcome Measures
NameTimeMethod
Percentage of Participants in MMS Clinical RemissionWeek 12
Percentage of Participants in MMS Clinical ResponseWeek 12
Percentage of Participants with Endoscopic RemissionWeek 12
Percentage of Participants with Endoscopic ImprovementWeek 12
Percentage of Participants Achieving Pediatric Ulcerative Colitis Activity Index (PUCAI) Clinical ResponseWeek 12
Percentage of Participants Achieving PUCAI Clinical RemissionWeek 52
Percentage of Participants Achieving Histologic Endoscopic Mucosal ImprovementWeek 52
Percentage of Participants Achieving MMS Clinical ResponseWeek 52
Percentage of Participants Achieving MMS Clinical RemissionWeek 52
Percentage of Participants Achieving PUCAI Clinical ResponseWeek 52
Percentage of Participants Achieving Endoscopic RemissionWeek 52
Percentage of Participants Achieving Endoscopic ImprovementWeek 52
Percentage of Participants Achieving MMS Clinical Remission without Surgery at Week 52 among Clinical Responders at Week 12 and without the Use of CorticosteroidsBaseline to Week 52
Pharmacokinetics (PK): Area Under the Curve (AUC) of MirikizumabBaseline to Week 52

PK: AUC of Mirikizumab

PK: Cmax of MirikizumabBaseline to Week 52

Trial Locations

Locations (56)

Rady Children's Hospital- San Diego

🇺🇸

San Diego, California, United States

University of California-San Francisco-Mission Bay

🇺🇸

San Francisco, California, United States

Connecticut Children's Medical Center

🇺🇸

Hartford, Connecticut, United States

GI Care for Kids

🇺🇸

Atlanta, Georgia, United States

Riley Childrens Hospital

🇺🇸

Indianapolis, Indiana, United States

Massachusetts General Hospital for Children

🇺🇸

Boston, Massachusetts, United States

Hadassah University Hospital - Mount Scopus

🇮🇱

Jerusalem, Israel

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

St. Louis Children's Hospital

🇺🇸

Saint Louis, Missouri, United States

Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

Cincinnati Childrens Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

Pediatric Gastroenterology Prisma Health - Upstate

🇺🇸

Greenville, South Carolina, United States

UZA

🇧🇪

Edegem, Belgium

UZ Leuven

🇧🇪

Leuven, Belgium

IWK Health Centre

🇨🇦

Halifax, Nova Scotia, Canada

London Health Sciences Centre (LHSC) - Victoria Hospital

🇨🇦

London, Ontario, Canada

The Hospital for Sick Children

🇨🇦

Toronto, Ontario, Canada

CHU Amiens - Picardie Site Sud

🇫🇷

Amiens, Somme, France

Groupement Hospitalier Est

🇫🇷

Bron, France

Hôpital Armand Trousseau

🇫🇷

Paris, France

Hôpital Necker - Enfants Malades

🇫🇷

Paris, France

LMU-Campus Innenstadt

🇩🇪

Muenchen, Bayern, Germany

Helios Klinikum Wuppertal

🇩🇪

Wuppertal, Nordrhein Westfalen, Germany

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

🇩🇪

Mainz, Rheinland Pfalz, Germany

Rambam Health Care Campus

🇮🇱

Haifa, Israel

Shaare Zedek Medical Center

🇮🇱

Jerusalem, Israel

Schneider Children's Medical Center

🇮🇱

Petach-Tikva, Israel

Shamir Medical Center

🇮🇱

Zerifin, Israel

Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer

🇮🇹

Firenze, Italy

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

🇮🇹

Roma, Italy

Ospedale Pediatrico Bambino Gesù

🇮🇹

Roma, Italy

Kokikai Tsujinaka Hospital Kashiwanoha

🇯🇵

Kashiwa-shi, Chiba-Ken, Japan

Yokohama City University Medical Center, Center of IBD

🇯🇵

Yokohama-shi, Kanagawa-Ken, Japan

Mie University Hospital

🇯🇵

Tsu-Shi, Mie-Ken, Japan

Juntendo University Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Tokyo Medical and Dental University Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

National Center for Child Health and Development

🇯🇵

Setagaya-ku, Tokyo, Japan

Saga University Hospital

🇯🇵

Saga, Japan

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

Kyungpook National University Medical Center Chilgok Hospital

🇰🇷

Deagu, Taegu-Kwangyǒkshi, Korea, Republic of

Inje University Haeundae Paik Hospital

🇰🇷

Busan, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Amsterdam UMC, locatie AMC

🇳🇱

Amsterdam, Netherlands

Erasmus Medisch Centrum

🇳🇱

Rotterdam, Netherlands

Korczowski Bartosz, Gabinet Lekarski

🇵🇱

Rzeszow, Poland

Twoja Przychodnia-Szczecinskie Centrum Medyczne Sp. z o. o.

🇵🇱

Szczecin, Poland

Warsaw IBD Point Profesor Kierkus

🇵🇱

Warszawa, Poland

Instytut "Pomnik - Centrum Zdrowia Dziecka"

🇵🇱

Warszaw, Poland

Centrum Medyczne Oporow

🇵🇱

Wroclaw, Poland

Hospital de Braga

🇵🇹

Braga, Portugal

Centro Hospitalar de São João, E.P.E.

🇵🇹

Porto, Portugal

King's College Hospital

🇬🇧

London, Greater London, United Kingdom

Sheffield Children's Hospital

🇬🇧

Sheffield, South Yorkshire, United Kingdom

Children's Clinical Research Facility

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath